<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer Milan</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3072476</article-id><article-id pub-id-type="pmid">21170567</article-id><article-id pub-id-type="publisher-id">256</article-id><article-id pub-id-type="doi">10.1007/s10194-010-0256-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Overview of diagnosis and management of paediatric headache. Part II: therapeutic management</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Termine</surname><given-names>Cristiano</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>&#x000d6;zge</surname><given-names>Aynur</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Antonaci</surname><given-names>Fabio</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Natriashvili</surname><given-names>Sophia</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Guidetti</surname><given-names>Vincenzo</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>W&#x000f6;ber-Bing&#x000f6;l</surname><given-names>&#x000c7;i&#x000e7;ek</given-names></name><address><phone>+43-1-404003044</phone><email>yasar.woeber-bingoel@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label>Child Neuropsychiatry Unit, Department of Experimental Medicine, University of Insubria, Como, Italy </aff><aff id="Aff2"><label>2</label>Department of Neurology, Mersin University School of Medicine, Mersin, Turkey </aff><aff id="Aff3"><label>3</label>Unit of Pavia, University Center for Adaptive Disorders and Headache (UCADH), Pavia, Italy </aff><aff id="Aff4"><label>4</label>Department of Psychiatry of Childhood and Adolescence, Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18&#x02013;20, 1090 Vienna, Austria </aff><aff id="Aff5"><label>5</label>Department of Child and Adolescent Neuropsychiatry, University La Sapienza, Rome, Italy </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>12</month><year>2010</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>12</month><year>2010</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2011</year></pub-date><volume>12</volume><issue>1</issue><fpage>25</fpage><lpage>34</lpage><history><date date-type="received"><day>15</day><month>3</month><year>2010</year></date><date date-type="accepted"><day>7</day><month>9</month><year>2010</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag 2010</copyright-statement></permissions><abstract id="Abs1"><p>A thorough evaluation of headache in children and adolescents is necessary to make the correct diagnosis and initiate treatment. In part 1 of this article (&#x000d6;zge et al. in J Headache Pain, <xref ref-type="bibr" rid="CR1">2010</xref>), we reviewed the diagnosis of headache in children and adolescents. In the present part, we will discuss therapeutic management of primary headaches. An appropriate management requires an individually tailored strategy giving due consideration to both non-pharmacological and pharmacological measures. Non-pharmacological treatments include relaxation training, biofeedback training, cognitive-behavioural therapy, different psychotherapeutic approaches or combinations of these treatments. The data supporting the effectiveness of these therapies are less clear-cut in children than in adults, but that is also true for the data supporting medical treatment. Management of migraine and TTH should include strategies relating to daily living activities, family relationships, school, friends and leisure time activities. In the pharmacological treatment age and gender of children, headache diagnosis, comorbidities and side effects of medication must be considered. The goal of symptomatic treatment should be a quick response with return to normal activity and without relapse. The drug should be taken as early as possible and in the appropriate dosage. Supplementary measures such as rest in a quiet, darkened room is recommended. Pharmaco-prophylaxis is only indicated if lifestyle modification and non-pharmacological prophylaxis alone are not effective. Although many prophylactic medications have been tried in paediatric migraine, there are only a few medications that have been studied in controlled trials. Multidisciplinary treatment is an effective strategy for children and adolescents with improvement of multiple outcome variants including frequency and severity of headache and school days missed because of headache. As a growing problem both children and families should be informed about medication overuse and the children&#x02019;s drug-taking should be checked.</p></abstract><kwd-group><title>Keywords</title><kwd>Migraine</kwd><kwd>Tension-type headache</kwd><kwd>Symptomatic treatment</kwd><kwd>Pharmacological prophylaxis</kwd><kwd>Non-pharmacological treatment</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2011</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Headache is the most common complaint in children and adolescents. The incidence of childhood migraine and frequent headache has substantially increased over the past 30&#x000a0;years. The increased incidence is alarming and may be secondary to lifestyle changes but also due to increased awareness of the disease in this age group. Primary headache (especially migraine and tension type headache, TTH) is the most important cause of headaches in this age group. In part 1 of this article [<xref ref-type="bibr" rid="CR1">1</xref>] we reviewed the diagnosis of headache in children and adolescents. In the present part, we will discuss therapeutic management.</p></sec><sec id="Sec2"><title>Management of headaches</title><p>The general principles of management of headache in children and adolescents can be summarized as follows:<list list-type="bullet"><list-item><p>Establish the diagnosis.</p></list-item><list-item><p>Look for possible somatic and psychiatric comorbidities [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>].</p></list-item><list-item><p>Ask for triggers and assess degree of disability.</p></list-item><list-item><p>Educate the child and family about the condition.</p></list-item><list-item><p>Use a headache calendar to establish the characteristics of headache and associated symptoms.</p></list-item><list-item><p>Establish realistic expectations and set appropriate goals.</p></list-item><list-item><p>Discuss the expected benefits of pharmacological and non-pharmacological therapy and the time course to achieve them.</p></list-item><list-item><p>Reduce the emotional mechanisms (on a personal level, within the family and at school) that provoke stress and may favour headache attacks.</p></list-item><list-item><p>Advise to maintain a sound rhythm in daily life, which includes regular meals, sufficient fluid intake, physical exercise and sleep.</p></list-item><list-item><p>Advise how to cope with trigger factors.</p></list-item></list></p><p>An algorithm for the diagnostic and therapeutic management of migraine is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Algorithm for the diagnostic and therapeutic management of migraine</p></caption><graphic xlink:href="10194_2010_256_Fig1_HTML" id="MO1"/></fig></p><sec id="Sec3"><title>Non-pharmacological treatments</title><sec id="Sec4"><title>Non-pharmacological treatment of migraine</title><p>Behavioural interventions, particularly biofeedback and relaxation therapy have demonstrated their effectiveness in the treatment of both adults and older children with migraine in controlled trials. The physiological basis for their effectiveness is unclear, but data from one trial suggest that levels of plasma beta-endorphin can be altered by relaxation and biofeedback therapies. The data supporting the effectiveness of behavioural therapies are less clear-cut in children than in adults, but that is also true for the data supporting medical treatment. This is due in part to methodological issues, especially the lack of specific tests for migraine, which has hampered research and helped leading to an inappropriate de-emphasis on care for childhood headache. In addition, migraine headaches in children are often briefer and have a higher rate of spontaneous remission than those experienced by adults, making it difficult to separate effective from ineffective treatments [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Starting from the consideration that children and adolescents with headache show greater indices of psychopathology [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>] and show higher risk of developing psychological disorders in adulthood than healthy controls [<xref ref-type="bibr" rid="CR15">15</xref>], different psychotherapeutic approaches are sometimes provided in clinical practice. Relaxation and cognitive-behavioural techniques have been found to reduce the intensity and frequency of headache in children and adolescents [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Prospective, randomized, partly double-blind, placebo-controlled, parallel-group trial showed that Butterbur root extract and music therapy might be superior to placebo and may represent promising treatment approaches in the prophylaxis of paediatric migraine [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>The specialists involved in the assessment and care of headache patients should strive to increase their knowledge of alternative therapies, so as to be better equipped to guide patients towards safe, economical and potentially effective treatments, rather than useless, costly or dangerous ones.</p></sec><sec id="Sec5"><title>Non-pharmacological treatment of TTH</title><p>Behavioural headache treatments include relaxation training, biofeedback training, cognitive-behavioural therapy or combinations of these treatments. Among behavioural headache treatments, the two most common types of biofeedback for headache have been electromyographic biofeedback for TTH and &#x0201c;handwarming&#x0201d; or thermal biofeedback for migraine [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Magnesium salt seems to be effective in treating the paediatric episodic and chronic TTH (ETTH, CTTH), but further well-controlled studies are needed [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>There are restricted data about the natural history of childhood and adolescent TTH. It is accepted that over than 50% of the sufferers improve with a comprehensive headache managements. The most important predictors of prognosis are comorbid medical and psychological conditions and family problems [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p></sec></sec><sec id="Sec6"><title>Pharmacological treatments</title><sec id="Sec7"><title>Pharmacological treatment of migraine</title><p>The data on efficacy and safety of medications in children are limited. Therefore, it may be necessary to use medications off label strictly weighing up the benefits and risks. However, medications which have shown efficacy in adults must not be used routinely in younger patients (please refer to Ref. [<xref ref-type="bibr" rid="CR26">26</xref>]). Only few randomized placebo-controlled clinical trials have been conducted in paediatric headache patients for both acute and preventive drugs. Moreover, the few published studies show a high placebo response rate in children, up to 55% for prophylactic drugs, up to 69% for symptomatic ones. Such high placebo response rates drastically reduce the possibility to find effective agents (in terms of statistically significant superiority over placebo) and may lower the interest of pharmaceutical companies and independent researchers to perform new clinical trials in this field. On the other hand, the placebo effect is a psychobiological phenomenon that can be attributed to different mechanisms [<xref ref-type="bibr" rid="CR27">27</xref>]; it should be properly used by the physician, simply bearing in mind that any medical treatment is surrounded by a psychosocial context that affects the therapeutic outcome.</p><p>The pharmacological treatment of migraine consists of symptomatic and/or prophylactic therapy. The former is aimed at relieving or ameliorating the symptoms of an acute attack, whereas prophylactic therapy, which requires the daily intake of medication for a certain period of time, decreases the frequency of the attacks and the severity of pain.</p><sec id="Sec8"><title>Symptomatic drug treatment</title><p>The goal of treatment should be a quick response with return to normal activity and without relapse. Several key concepts should be made known to patients. Medication use should be limited to avoid medication overuse headache. It is important that an appropriate dose is used. Medications should be taken shortly after onset of migraine headache to optimize the effect, even though scientific evidence supporting this recommendation is lacking. The medication should be available to the patients also at school. Allodynia during a migraine in adults correlates with response to treatment of acute migraine with triptans and the progressive nature of migraine. This has emphasized the importance of early recognition of headache and appropriate treatment. Allodynia has recently been shown to be present in 37% of children during their migraine. Allodynia is often not routinely evaluated during a headache history even though there may be potential therapeutic implications. Prominent scalp symptoms include sensitivity to touch and difficulty brushing hair [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>].</p><p>The available efficacy data about symptomatic drugs [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>] are summarized in Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>. The following findings should be kept in mind:<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Symptomatic drugs for migraine management evaluated in placebo-controlled and open clinical trials</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">References</th><th align="left" rowspan="2">Drug</th><th align="left" rowspan="2">Study design</th><th align="left" rowspan="2">Evidence level</th><th align="left" rowspan="2">Dose</th><th align="left" rowspan="2">Age (years)</th><th align="left" rowspan="2">Number of patients</th><th align="left" colspan="2">Responders (%)</th><th align="left" rowspan="2"><italic>p</italic> value</th></tr><tr><th align="left">Active drug</th><th align="left">Placebo</th></tr></thead><tbody><tr><td align="left">Hamalainen et al. [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">Ibuprofen</td><td align="left">RCT</td><td char="." align="char" rowspan="3">A</td><td align="left">10&#x000a0;mg/kg</td><td char="&#x02013;" align="char">4&#x02013;16</td><td char="." align="char">88</td><td char="." align="left">68</td><td char="." align="char">37</td><td align="left">&#x0003c;0.05</td></tr><tr><td align="left">Lewis et al. [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">Ibuprofen</td><td align="left">RCT</td><td align="left">7.5&#x000a0;mg/kg</td><td char="&#x02013;" align="char">6&#x02013;12</td><td char="." align="char">84</td><td char="." align="left">76</td><td char="." align="char">53</td><td align="left">0.006</td></tr><tr><td align="left">Evers et al. [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left">Ibuprofen</td><td align="left">RCT</td><td align="left">200&#x02013;400&#x000a0;mg</td><td char="&#x02013;" align="char">6&#x02013;18</td><td char="." align="char">32</td><td char="." align="left">69</td><td char="." align="char">28</td><td align="left">&#x0003c;0.05</td></tr><tr><td align="left">Hamalainen [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">Acetaminophen</td><td align="left">RCT</td><td char="." align="char">B</td><td align="left">15&#x000a0;mg/kg</td><td char="&#x02013;" align="char">4&#x02013;16</td><td char="." align="char">88</td><td char="." align="left">54</td><td char="." align="char">37</td><td align="left">&#x0003c;0.05</td></tr><tr><td align="left">Hamalainen et al. [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left">Dihydroergotamine</td><td align="left">RCT</td><td char="." align="char">C</td><td align="left">20, 40&#x000a0;&#x003bc;g/kg</td><td char="&#x02013;" align="char">5&#x02013;15</td><td char="." align="char">12</td><td char="." align="left">58</td><td char="." align="char">16</td><td align="left">NS</td></tr><tr><td align="left">Ueberall [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left">Sumatriptan nasal</td><td align="left">RCT</td><td char="." align="char" rowspan="4">A</td><td align="left">20&#x000a0;mg</td><td char="&#x02013;" align="char">6&#x02013;10</td><td char="." align="char">14</td><td char="." align="left">86</td><td char="." align="char">43</td><td align="left">0.03</td></tr><tr><td align="left">Winner et al. [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="left">Sumatriptan nasal</td><td align="left">RCT</td><td align="left">5&#x02013;10&#x02013;20&#x000a0;mg</td><td char="&#x02013;" align="char">12&#x02013;17</td><td char="." align="char">510</td><td char="." align="left">66<sup>a</sup></td><td char="." align="char">53</td><td align="left">&#x0003c;0.05</td></tr><tr><td align="left">Ahonen et al. [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left">Sumatriptan nasal</td><td align="left">RCT</td><td align="left">10&#x02013;20&#x000a0;mg</td><td char="&#x02013;" align="char">8&#x02013;17</td><td char="." align="char">83</td><td char="." align="left">64</td><td char="." align="char">39</td><td align="left">0.003</td></tr><tr><td align="left">Winner et al. [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left">Sumatriptan nasal</td><td align="left">RCT</td><td align="left">20&#x000a0;mg</td><td char="&#x02013;" align="char">12&#x02013;17</td><td char="." align="char">738</td><td align="left">61</td><td char="." align="char">52</td><td align="left">NS</td></tr><tr><td align="left">Hamalainen et al. [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left">Sumatriptan oral</td><td align="left">RCT</td><td char="." align="char">C</td><td align="left">50&#x02013;100&#x000a0;mg</td><td char="&#x02013;" align="char">8&#x02013;16</td><td char="." align="char">23</td><td align="left">30</td><td char="." align="char">22</td><td align="left">NS</td></tr><tr><td align="left">Mac Donald [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left">Sumatriptan sc.</td><td align="left">OT</td><td char="." align="char" rowspan="2">C</td><td align="left">3&#x02013;6&#x000a0;mg</td><td char="&#x02013;" align="char">6&#x02013;16</td><td char="." align="char">17</td><td align="left">64</td><td char="." align="char">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Linder [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td align="left">Sumatriptan sc.</td><td align="left">OT</td><td align="left">0.06&#x000a0;mg/kg</td><td char="&#x02013;" align="char">6&#x02013;18</td><td char="." align="char">50</td><td align="left">78</td><td char="." align="char">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Winner et al. [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">Rizatriptan</td><td align="left">RCT</td><td char="." align="char" rowspan="3">C</td><td align="left">5&#x000a0;mg</td><td char="&#x02013;" align="char">12&#x02013;17</td><td char="." align="char">196</td><td align="left">66</td><td char="." align="char">56</td><td align="left">NS</td></tr><tr><td align="left">Visser et al. [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left">Rizatriptan</td><td align="left">RCT</td><td align="left">5&#x000a0;mg</td><td char="&#x02013;" align="char">12&#x02013;17</td><td char="." align="char">234</td><td align="left">68</td><td char="." align="char">69</td><td align="left">NS</td></tr><tr><td align="left">Visser et al. [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left">Rizatriptan</td><td align="left">OT</td><td align="left">5&#x000a0;mg</td><td char="&#x02013;" align="char">12&#x02013;17</td><td char="." align="char">686</td><td align="left">77</td><td char="." align="char">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Linder and Dowson [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left">Zolmitriptan oral</td><td align="left">OT</td><td char="." align="char" rowspan="2">C</td><td align="left">2.5&#x02013;5&#x000a0;mg</td><td char="&#x02013;" align="char">12&#x02013;17</td><td char="." align="char">38</td><td char="." align="left">88&#x02013;70</td><td char="." align="char">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Evers et al. [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left">Zolmitriptan oral</td><td align="left">RCT</td><td align="left">2.5&#x000a0;mg</td><td char="&#x02013;" align="char">6&#x02013;18</td><td char="." align="char">32</td><td char="." align="left">62</td><td char="." align="char">28</td><td align="left">&#x0003c;0.05</td></tr><tr><td align="left">Charles [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left">Almotriptan oral</td><td align="left">OT</td><td char="." align="char" rowspan="2">B</td><td align="left">6.25&#x02013;12.5&#x000a0;mg</td><td char="&#x02013;" align="char">11&#x02013;17</td><td char="." align="char">15</td><td align="left">86</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Linder et al. [<xref ref-type="bibr" rid="CR46">46</xref>]</td><td align="left">Almotriptan oral</td><td align="left">RCT</td><td align="left">6.25&#x02013;12.5&#x02013;25&#x000a0;mg</td><td char="&#x02013;" align="char">12&#x02013;17</td><td char="." align="char">866</td><td align="left">67&#x02013;73</td><td align="left">55</td><td align="left">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>Evidence level: findings regarding symptomatic drugs were reviewed and the recommendations were categorized into different levels (A&#x02013;C) [<xref ref-type="bibr" rid="CR47">47</xref>]. Level A: two or more clinically controlled, randomized studies carried out according to good clinical practice (GCP), versus placebo or versus active treatment of proven efficacy. Level B: one clinically controlled, randomized study carried out according to GCP or more than one well-designed clinical case&#x02013;control study or cohort study. Level C: favourable judgment of two-third of the Ad Hoc Committee members, historical controls, non-randomized studies, case reports</p><p><italic>NS</italic> no statistically significant difference between active drug and placebo, <italic>RCT</italic> randomized controlled trial, <italic>OT</italic> open trial</p><p><sup>a</sup>5&#x000a0;mg</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Summary of the efficacy of medication used to treat acute migraine attacks in children and adolescents [<xref ref-type="bibr" rid="CR45">45</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="4">Outcome</th></tr><tr><th align="left">Pain relief</th><th align="left">Pain-free</th><th align="left">Recurrence</th><th align="left">Need for rescue medications</th></tr></thead><tbody><tr><td align="left" colspan="5">Oral medication</td></tr><tr><td align="left">&#x000a0;Acetaminophen (<italic>n</italic>&#x000a0;=&#x000a0;1)</td><td align="left">+</td><td align="left">&#x02212;</td><td align="left">&#x02212;</td><td align="left">&#x02212;</td></tr><tr><td align="left">&#x000a0;DHE (<italic>n</italic>&#x000a0;=&#x000a0;1)</td><td align="left">&#x02212;</td><td align="left">&#x02212;</td><td align="left">&#x02212;</td><td align="left">&#x02212;</td></tr><tr><td align="left">&#x000a0;Ibuprofen (<italic>n</italic>&#x000a0;=&#x000a0;3)</td><td align="left">+</td><td align="left">&#x000b1;</td><td align="left">&#x02212;</td><td align="left">&#x000b1;</td></tr><tr><td align="left">&#x000a0;Rizatriptan (<italic>n</italic>&#x000a0;=&#x000a0;3)</td><td align="left">&#x000b1;</td><td align="left">&#x02212;</td><td align="left">&#x02212;</td><td align="left">&#x000b1;</td></tr><tr><td align="left">&#x000a0;Sumatriptan (<italic>n</italic>&#x000a0;=&#x000a0;1)</td><td align="left">&#x02212;</td><td align="left">&#x000b1;</td><td align="left">&#x02212;</td><td align="left">&#x02212;</td></tr><tr><td align="left">&#x000a0;Zolmitriptan (<italic>n</italic>&#x000a0;=&#x000a0;2)</td><td align="left">&#x000b1;</td><td align="left">&#x000b1;</td><td align="left">&#x02212;</td><td align="left">+</td></tr><tr><td align="left" colspan="5">Intranasal medication</td></tr><tr><td align="left">&#x000a0;Sumatriptan (<italic>n</italic>&#x000a0;=&#x000a0;4)</td><td align="left">&#x000b1;</td><td align="left">&#x000b1;</td><td align="left">&#x02212;</td><td align="left">&#x000b1;</td></tr><tr><td align="left" colspan="5">Intravenous medications</td></tr><tr><td align="left">&#x000a0;Prochlorperazine (<italic>n</italic>&#x000a0;=&#x000a0;1)</td><td align="left">+</td><td align="left">?</td><td align="left">&#x02212;</td><td align="left">?</td></tr><tr><td align="left">&#x000a0;Ketorolac (<italic>n</italic>&#x000a0;=&#x000a0;1)*</td><td align="left">?</td><td align="left">?</td><td align="left">?</td><td align="left">? &#x000b1;</td></tr></tbody></table><table-wrap-foot><p>+ studies showing consistent positive results or a study showing positive result; &#x02212; studies showing consistent negative results or a study showing negative result; &#x000b1; studies showing inconsistent results; ? not evaluated</p><p>*&#x000a0;Used as a comparative agent against prochlorperazine</p></table-wrap-foot></table-wrap><list list-type="bullet"><list-item><p>At 1&#x000a0;h acetaminophen tended to be slightly more effective (39% of children relieved) than ibuprofen (37% of children relieved), but 2&#x000a0;h after administration ibuprofen was more effective (68 vs. 54%).</p></list-item><list-item><p>Sumatriptan nasal spray was superior to placebo and was well tolerated. No serious adverse events occurred with taste disturbance as the most common one.</p></list-item><list-item><p>Pain relief at 2&#x000a0;h was achieved in significantly more attacks treated with rizatriptan 5-mg tablets (77%) or with rizatriptan 5-mg wafer (77%) than with standard care (64%).</p></list-item><list-item><p>Pain relief rates after 2&#x000a0;h were 28% for placebo, 62% for zolmitriptan and 69% for ibuprofen (placebo vs. zolmitriptan <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05; placebo vs. ibuprofen <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05). Both drugs are well tolerated with only mild side effects.</p></list-item><list-item><p>The Food Drug Administration has recently approved almotriptan for the acute treatment of migraine headache in adolescents. Nevertheless, almotriptan is still not approved in Europe.</p></list-item><list-item><p>There are limited data about other triptans.</p></list-item><list-item><p>In summary, there is moderate evidence that analgesics (acetaminophen and ibuprofen) and nasal-spray sumatriptan are more effective than placebo treatment. Based on the available literature, no differences in effect were found between the different compounds.</p></list-item></list></p><p>There is a lack of studies addressing the question of treatment in the emergency department of children with migraine. Future studies should focus on finding the best first-line agent for mild to moderate attacks in the emergency department and to confirm the usefulness of prochlorperazine as treatment for severe attack or status migrainosus. In the latter studies, attention should be given to adverse drug reactions associated with prochlorperazine. Furthermore, treatment to decrease the recurrence of migraine attack and the need for rescue medications after discharge from the emergency department should also be carefully evaluated [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="Sec9"><title>Prophylactic drug treatment</title><p>Pharmaco-prophylaxis is only indicated if lifestyle modification and non-pharmacological prophylaxis alone are not effective. Although many prophylactic medications have been tried in paediatric migraine, there are only a few medications that have been studied in controlled trials. Prophylactic medications are recommended only when migraines are occurring with sufficient frequency (usually 3&#x02013;4 per month) and severity to impact a patient&#x02019;s daily function or quality of life (e.g. missing school). To minimize adverse effects, prophylactic medications are started at the lowest dose and titrated upward as needed. They have to give a through time period (at least 4&#x02013;6&#x000a0;months), and both comorbidities and side effects of the drug have to be taken into consideration [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR49">49</xref>].</p><p>Prophylactic drugs evaluated in placebo-controlled and open-label trials for migraine [<xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR71">71</xref>] have been summarized in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. The following findings should be kept in mind:<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Prophylactic drugs for migraine management evaluated in placebo-controlled and open clinical trials</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">References</th><th align="left">Drug</th><th align="left">Daily dose</th><th align="left">Age in (years)</th><th align="left">Number of patients</th><th align="left">Study design</th><th align="left">Evidence level</th><th align="left">% responders or <italic>p</italic> values (*)</th></tr></thead><tbody><tr><td align="left" colspan="8">Antihypertensive drugs</td></tr><tr><td align="left">&#x000a0;Ludvigsson [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left">Propranolol</td><td align="left">60&#x02013;120&#x000a0;mg</td><td align="left">7&#x02013;16</td><td char="." align="char">28</td><td align="left">RCT</td><td align="left" rowspan="3">C</td><td align="left">82 vs. 14%</td></tr><tr><td align="left">&#x000a0;Forsythe et al. [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left">Propranolol</td><td align="left">80&#x000a0;mg</td><td align="left">9&#x02013;15</td><td char="." align="char">39</td><td align="left">RCT</td><td align="left">NS</td></tr><tr><td align="left">&#x000a0;Olness et al. [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left">Propranolol</td><td align="left">3&#x000a0;mg/kg</td><td align="left">6&#x02013;12</td><td char="." align="char">28</td><td align="left">RCT</td><td align="left">NS</td></tr><tr><td align="left">&#x000a0;Sillamp&#x000e4;&#x000e4; [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left">Clonidine</td><td align="left">25&#x02013;50&#x000a0;&#x003bc;g</td><td align="left">&#x02264;15</td><td char="." align="char">57</td><td align="left">RCT</td><td align="left" rowspan="2">C</td><td align="left">NS</td></tr><tr><td align="left">&#x000a0;Sills et al. [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left">Clonidine</td><td align="left">0.07&#x02013;0.1&#x000a0;mg</td><td align="left">7&#x02013;14</td><td char="." align="char">43</td><td align="left">RCT</td><td align="left">NS</td></tr><tr><td align="left" colspan="8">Calcium channel blockers</td></tr><tr><td align="left">&#x000a0;Guidetti et al. [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left">Flunarizine</td><td align="left">5&#x000a0;mg</td><td align="left">10&#x02013;13</td><td char="." align="char">12</td><td align="left">OT</td><td align="left" rowspan="2">A</td><td align="left">66%</td></tr><tr><td align="left">&#x000a0;Sorge et al. [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">Flunarizine</td><td align="left">5&#x000a0;mg</td><td align="left">5&#x02013;11</td><td char="." align="char">63</td><td align="left">RCT</td><td align="left"><italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 (HA frequency)<break/><italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01 (HA duration)</td></tr><tr><td align="left">&#x000a0;Visudtibhan et al. [<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left">Flunarizine</td><td align="left">5&#x02013;10&#x000a0;mg</td><td align="left">7&#x02013;15</td><td char="." align="char">21</td><td align="left">OT</td><td align="left"/><td align="left">%66</td></tr><tr><td align="left">&#x000a0;Battistella et al. [<xref ref-type="bibr" rid="CR58">58</xref>]</td><td align="left">Nimodipine</td><td align="left">10&#x02013;20&#x000a0;mg</td><td align="left">7&#x02013;18</td><td char="." align="char">37</td><td align="left">RCT</td><td align="left">C</td><td align="left">NS</td></tr><tr><td align="left" colspan="8">Serotonergic drugs</td></tr><tr><td align="left">&#x000a0;Gillies et al. [<xref ref-type="bibr" rid="CR59">59</xref>]</td><td align="left">Pizotifen</td><td align="left">1&#x02013;1.5&#x000a0;mg</td><td align="left">7&#x02013;14</td><td char="." align="char">47</td><td align="left">RCT</td><td align="left">C</td><td align="left">NS</td></tr><tr><td align="left">&#x000a0;Lewis et al. [<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left">Cyproheptadine</td><td align="left">2&#x02013;8&#x000a0;mg</td><td align="left">3&#x02013;12</td><td char="." align="char">30</td><td align="left">OT</td><td align="left">C</td><td align="left">83%</td></tr><tr><td align="left" colspan="8">Antidepressants</td></tr><tr><td align="left">&#x000a0;Battistella et al. [<xref ref-type="bibr" rid="CR61">61</xref>]</td><td align="left">Trazodone</td><td align="left">1&#x000a0;mg/kg</td><td align="left">7&#x02013;18</td><td char="." align="char">35</td><td align="left">RCT</td><td align="left">C</td><td align="left">NS</td></tr><tr><td align="left">&#x000a0;Hershey et al. [<xref ref-type="bibr" rid="CR62">62</xref>]</td><td align="left">Amitriptyline</td><td align="left">1&#x000a0;mg/kg</td><td align="left">9&#x02013;15</td><td char="." align="char">192</td><td align="left">OT</td><td align="left" rowspan="2">C</td><td align="left">80%</td></tr><tr><td align="left">&#x000a0;Lewis et al. [<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left">Amitriptyline</td><td align="left">10&#x000a0;mg</td><td align="left">3&#x02013;12</td><td char="." align="char">73</td><td align="left">OT</td><td align="left">89%</td></tr><tr><td align="left" colspan="8">Anticonvulsants</td></tr><tr><td align="left">&#x000a0;Caruso et al. [<xref ref-type="bibr" rid="CR63">63</xref>]</td><td align="left">Divalproex sodium</td><td align="left">15&#x02013;45&#x000a0;mg/kg</td><td align="left">7&#x02013;16</td><td char="." align="char">42</td><td align="left">OT</td><td align="left" rowspan="2">B</td><td align="left">76%</td></tr><tr><td align="left">&#x000a0;Sedaroglu et al. [<xref ref-type="bibr" rid="CR64">64</xref>]</td><td align="left">Divalproex sodium</td><td align="left">500&#x02013;1,000&#x000a0;mg</td><td align="left">9&#x02013;17</td><td char="." align="char">10</td><td align="left">OT</td><td align="left"><italic>p</italic>&#x000a0;=&#x000a0;0.000 (HA severity)<break/><italic>p</italic>&#x000a0;=&#x000a0;0.002 (HA frequency)<break/><italic>p</italic>&#x000a0;=&#x000a0;0.001 (HAduration)</td></tr><tr><td align="left">&#x000a0;Hershey et al. [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td align="left">Topiramate</td><td align="left">1.4&#x000a0;&#x000b1;&#x000a0;0.7&#x000a0;mg/kg</td><td align="left">8&#x02013;15</td><td char="." align="char">75</td><td align="left">OT</td><td align="left" rowspan="3">A</td><td align="left"><italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 (HA frequency)</td></tr><tr><td align="left">&#x000a0;Winner et al. [<xref ref-type="bibr" rid="CR66">66</xref>]</td><td align="left">Topiramate</td><td align="left">2&#x02013;3&#x000a0;mg/kg</td><td align="left">6&#x02013;15</td><td char="." align="char">162</td><td align="left">RCT</td><td align="left">NS</td></tr><tr><td align="left">&#x000a0;Lewis et al. [<xref ref-type="bibr" rid="CR67">67</xref>]</td><td align="left">Topiramate</td><td align="left">100&#x000a0;mg</td><td align="left">12&#x02013;17</td><td char="." align="char">103</td><td align="left">RCT</td><td align="left">72%</td></tr><tr><td align="left">&#x000a0;Miller [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td align="left">Levetiracetam</td><td align="left">250&#x02013;1,500&#x000a0;mg</td><td align="left">3&#x02013;17</td><td char="." align="char">19</td><td align="left">OT</td><td align="left" rowspan="2">B</td><td align="left"><italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 (HA frequency)</td></tr><tr><td align="left">&#x000a0;Pekalnis et al. [<xref ref-type="bibr" rid="CR69">69</xref>]</td><td align="left">Levetiracetam</td><td align="left">250&#x02013;1,500&#x000a0;mg</td><td align="left">6&#x02013;17</td><td char="." align="char">20</td><td align="left">OT</td><td align="left"><italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 (HA frequency)</td></tr><tr><td align="left">&#x000a0;Belman et al. [<xref ref-type="bibr" rid="CR70">70</xref>]</td><td align="left">Gabapentin</td><td align="left">15&#x000a0;mg/kg</td><td align="left">6&#x02013;17</td><td char="." align="char">18</td><td align="left">OT</td><td align="left">C</td><td align="left">80%</td></tr><tr><td align="left">&#x000a0;Pakalnis and Kring [<xref ref-type="bibr" rid="CR71">71</xref>]</td><td align="left">Zonisamide</td><td align="left">5.8&#x000a0;mg/kg</td><td align="left">10&#x02013;17</td><td char="." align="char">12</td><td align="left">OT</td><td align="left">C</td><td align="left">66%</td></tr></tbody></table><table-wrap-foot><p>Evidence level: findings regarding symptomatic drugs were reviewed and the recommendations were categorized into different levels (A&#x02013;C) [<xref ref-type="bibr" rid="CR47">47</xref>]. Level A: two or more clinically controlled, randomized studies carried out according to good clinical practice (GCP), versus placebo or versus active treatment of proven efficacy. Level B: one clinically controlled, randomized study carried out according to GCP or more than one well-designed clinical case&#x02013;control study or cohort study. Level C: favourable judgment of two-thirds of the Ad Hoc Committee members, historical controls, non-randomized studies, case reports</p><p><italic>NS</italic> no statistically significant difference between active drug and placebo, <italic>HA</italic> headache, <italic>RCT</italic> randomized controlled trial, <italic>OT</italic> open trial</p><p>*&#x000a0;The % is expressed as overall % of responders (OT) or active-drug vs placebo % of responders (RCT); <italic>p</italic> values refer to active drug versus placebo comparisons (RCT) or pre-treatment versus post-treatment comparison of headache characteristics (OT)</p></table-wrap-foot></table-wrap><list list-type="bullet"><list-item><p>Flunarizine is an effective drug. Its use is limited by daytime sedation found in 10% of the patients and weight gain in more than 20%. Because of probable D2 receptor interaction it should not be given for more than 3&#x000a0;months (administering it in the early evening can avert daytime sleepiness, dosage 5&#x000a0;mg/die) [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>].</p></list-item><list-item><p>Propranolol was found to be superior to placebo in one randomized controlled trial and not effective in two others. It was found to activate asthma in subjects with atopic disorders or a positive history of atopic disorders, and there are no follow-up studies concerning long-term risks of betablockers. Therefore, some centres do not use betablockers for migraine prophylaxis in children.</p></list-item><list-item><p>The overall positive response rate of cyproheptadine was 83% and common side effects included sedation and increased appetite.</p></list-item><list-item><p>There are limited confirmative data about trazodone.</p></list-item><list-item><p>Amitriptyline (1&#x000a0;mg/kg) is an effective drug with an 84.2&#x02013;89% positive response rate and only mild sedation was reported as side effect.</p></list-item><list-item><p>Divalproex sodium (15&#x02013;45&#x000a0;mg/kg/day) is an effective drug with 50% headache reduction seen in 78.5% of patients, 75% reduction in 14.2% of patients, and 9.5% of patients became headache-free after 4&#x000a0;months of treatment. The observed side effects were dizziness, drowsiness and increase in appetite.</p></list-item><list-item><p>Topiramate is an effective drug for the reduction of headache frequency, severity and duration. The most common side effects reported were cognitive (12.5%), weight loss (5.6%) and sensory (2.8%).</p></list-item><list-item><p>There are limited data about levetiracetam, gabapentin and zonisamide.</p></list-item></list></p></sec></sec><sec id="Sec10"><title>Pharmacological treatment of TTH</title><p>Most TTH is best managed by primary care. ETTH is self-limiting, but children and their parents generally consult doctors when headaches occur frequently and are no longer responsive to analgesics. Medication overuse can be a common problem in patients with frequent headache. The treatment of migraine and TTH overlaps. Both require acute treatment, either behavioural or pharmaceutical. Behavioural treatment is needed for all types of TTH. Preventive pharmaceutical treatment is needed for frequent TTH if lifestyle modification and non-pharmacological treatment alone are not effective. Although childhood TTH is often treated with medication, few studies have been published the efficacy of medication in paediatric TTH. More studies in children need to be done regarding the treatment of this common disorder. The lack of availability and cost of non-pharmacological interventions might diminish the use of some treatment modalities [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>].</p><p>For acute treatment of ETTH, paracetamol, aspirin and combination analgesics are effective and inexpensive drugs. Non-steroidal anti-inflammatory drugs are also effective first-line therapeutics for ETTH in adults. In children younger than 15&#x000a0;years, aspirin is not recommended because of the concern regarding Reye&#x02019;s syndrome. Paracetamol seems to be safe even in young children [<xref ref-type="bibr" rid="CR75">75</xref>&#x02013;<xref ref-type="bibr" rid="CR78">78</xref>].</p><p>Frequent headaches in children and adolescents often require preventive management. Prophylactic pharmacological treatment should be considered in CTTH if non-pharmacological management is inadequate. For children with frequent headache, amitriptyline might be beneficial, although no placebo-controlled studies have been performed [<xref ref-type="bibr" rid="CR62">62</xref>].</p></sec></sec><sec id="Sec11"><title>Treatment of cluster headache</title><p>Several treatment alternatives have been tried in cases reported in the literature. According to these data, the most effective symptomatic treatments are oxygen [<xref ref-type="bibr" rid="CR79">79</xref>&#x02013;<xref ref-type="bibr" rid="CR82">82</xref>], sumatriptan [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR83">83</xref>] and acetylsalicylic acid [<xref ref-type="bibr" rid="CR80">80</xref>&#x02013;<xref ref-type="bibr" rid="CR84">84</xref>]. Prophylactic treatments reported in literature are prednisone/prednisolone [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR86">86</xref>], indomethacin [<xref ref-type="bibr" rid="CR84">84</xref>], pizotifen [<xref ref-type="bibr" rid="CR81">81</xref>], verapamil [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR87">87</xref>], methysergide [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR85">85</xref>], loratadine [<xref ref-type="bibr" rid="CR88">88</xref>], astemizole [<xref ref-type="bibr" rid="CR88">88</xref>] and flunarizine [<xref ref-type="bibr" rid="CR89">89</xref>]. No controlled study has been reported.</p><p>If oxygen is administered at the onset of an attack via a non-rebreathing facial mask at a flow rate of at least 7&#x000a0;l/min, approximately 70% of patients will obtain pain relief within 15&#x000a0;min. This therapy has obvious practical limitations and requires oxygen being readily available at the patient&#x02019;s home [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. Considering the unbearable pain intensity, off-label use of sumatriptan nasal spray or subcutaneous sumatriptan may be necessary. Ergotamine has also been used. It is not recommended for acute CH-treatment in children, but might be given in the evening for preventing night-time attacks. Children between 6 and 9&#x000a0;years of age should receive 0.1&#x000a0;mg/dose, those between 9 and 12&#x000a0;years of age should receive 0.5&#x000a0;mg, and those between 12 and 16&#x000a0;years of age should receive 0.75&#x000a0;mg/dose. Lidocaine applied with a spray bottle or by dropping in the nostril ipsilateral to pain achieves moderate pain relief, and it may be useful as an adjunctive therapy. Although the reason for steroid efficacy is unknown, the use of cortisone in the acute period can stop the attacks and may help to prevent further attacks. In adolescents a marked relief of cluster headache in 77% of 77 episodic cluster headache patients, and a partial relief in another 12% of patients treated with prednisone was reported [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. For prophylactic treatment the efficacy of verapamil has been attributed to a possible stabilization of vascular tone. It is generally well tolerated and can be used in combination with corticosteroids, sumatriptan and ergotamine [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>].</p></sec></sec><sec id="Sec12"><title>Life quality of headaches</title><p>Health-related quality of life (QOL) is an emerging area of headache research with a direct impact on patient adherence, patient satisfaction and treatment effectiveness. On the other hand, the assessment of QOL in children is difficult, since measures must consider children&#x02019;s changing cognitive and social development [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. Data-based analyses revealed that children with frequent or severe headaches (FSH) were significantly more likely than those without FSH to exhibit high levels of emotional, conduct, inattention-hyperactivity, and peer problems and were significantly more likely than children without FSH to be upset or distressed by their difficulties and to have their difficulties interfere with home life, friendships, classroom learning and leisure activities [<xref ref-type="bibr" rid="CR95">95</xref>]. Subjects familiar with headache experienced more stress, fatigue, depression, and somatic symptoms; they felt less strong, had a less cheerful mood and reported lower satisfaction with health and with life in general than the subjects who never had headaches [<xref ref-type="bibr" rid="CR96">96</xref>]. The impact of headaches on QOL is similar to that found for other chronic illness conditions, with impairments in school and emotional functioning being the most prominent [<xref ref-type="bibr" rid="CR97">97</xref>]. Headache is the third most common cause among illness-related causes of school absenteeism resulting in substantial impairment among paediatric patients [<xref ref-type="bibr" rid="CR98">98</xref>]. A specific questionnaire (PedMIDAS) provides a tool to assess the impact of migraines in children and to monitor response to treatment. Further research should focus on additional validation of the PedMIDAS using a larger population and sampling from other populations (e.g. primary care and community samples) [<xref ref-type="bibr" rid="CR99">99</xref>].</p></sec><sec id="Sec13"><title>Conclusions</title><p><list list-type="bullet"><list-item><p>Management of migraine and TTH should include strategies relating to daily living activities, family relationships, school, friends and leisure time activities.</p></list-item><list-item><p>Management should be completed by education (both of the children and parents), non-pharmacological interventions and psychosocial support.</p></list-item><list-item><p>With reference to symptomatic treatment, the drug should be taken as early as possible and in the appropriate dosage. In cases with early onset of nausea and/or vomiting endorectal or parenteral administration should be preferred. Antiemetic drugs should not be provided if the child vomits only once or headache stops after vomiting. If an antiemetic is required, ondansetron may be preferred for its good tolerability. Supplementary measures such as rest in a quiet, darkened room is recommended.</p></list-item><list-item><p>Multidisciplinary treatment is an effective strategy for children and adolescents with improvement of multiple outcome variants including frequency and severity of headache and school days missed because of headache.</p></list-item><list-item><p>In the pharmacological treatment age and gender of children, headache diagnosis, comorbidities, need and side effects of medication must be considered.</p></list-item><list-item><p>As a growing problem both children and families should be informed about medication overuse and the children&#x02019;s drug-taking should be checked.</p></list-item><list-item><p>Regular follow-up care is needed, especially for those children with more severe initial headache presentation.</p></list-item></list></p></sec></body><back><ack><p><bold>Conflict of interest</bold> None.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">&#x000d6;zge A, Termine C, Antonaci F, Natriashvili S, Guidetti V, W&#x000f6;ber-Bing&#x000f6;l &#x000c7; (2010) Overview of the diagnosis	and management of paediatric headache. Part I&#x02014;diagnosis. J Headache Pain</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidetti</surname><given-names>V</given-names></name><name><surname>Galli</surname><given-names>F</given-names></name></person-group><article-title>Psychiatric comorbidity in chronic daily headache: pathophysiology, etiology, and diagnosis</article-title><source>Curr Pain Headache Rep</source><year>2002</year><volume>6</volume><issue>6</issue><fpage>492</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1007/s11916-002-0069-7</pub-id><pub-id pub-id-type="pmid">12413409</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e4;m&#x000e4;l&#x000e4;inen</surname><given-names>ML</given-names></name></person-group><article-title>Migraine in children. Guidelines for treatment</article-title><source>CNS Drugs</source><year>1998</year><volume>10</volume><fpage>105</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.2165/00023210-199810020-00003</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruni</surname><given-names>O</given-names></name><name><surname>Galli</surname><given-names>F</given-names></name><name><surname>Guidetti</surname><given-names>V</given-names></name></person-group><article-title>Sleep hygiene and migraine in children and adolescents</article-title><source>Cephalalgia</source><year>1999</year><volume>19</volume><issue>Suppl. 25</issue><fpage>S57</fpage><lpage>S59</lpage></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>W&#x000f6;ber</surname><given-names>C</given-names></name><name><surname>W&#x000f6;ber-Bing&#x000f6;l</surname><given-names>&#x000c7;</given-names></name></person-group><article-title>Clinical management of young patients presenting with headache</article-title><source>Funct Neurol</source><year>2000</year><volume>15</volume><issue>Suppl. 3</issue><fpage>S89</fpage><lpage>S105</lpage></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carotenuto</surname><given-names>M</given-names></name><name><surname>Guidetti</surname><given-names>V</given-names></name><name><surname>Ruju</surname><given-names>F</given-names></name><name><surname>Galli</surname><given-names>F</given-names></name><name><surname>Tagliente</surname><given-names>FR</given-names></name><name><surname>Pascotto</surname><given-names>A</given-names></name></person-group><article-title>Headache disorders as risk factors for sleep disturbances in school aged children</article-title><source>J Headache Pain</source><year>2005</year><volume>6</volume><issue>4</issue><fpage>268</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1007/s10194-005-0204-z</pub-id><pub-id pub-id-type="pmid">16362683</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damen</surname><given-names>L</given-names></name><name><surname>Bruijn</surname><given-names>J</given-names></name><name><surname>Koes</surname><given-names>BW</given-names></name><name><surname>Berger</surname><given-names>MY</given-names></name><name><surname>Passchier</surname><given-names>J</given-names></name><name><surname>Verhagen</surname><given-names>AP</given-names></name></person-group><article-title>Prophylactic treatment of migraine in children. Part 1: a systematic review of non-pharmacological trials</article-title><source>Cephalalgia</source><year>2005</year><volume>6</volume><fpage>373</fpage><lpage>383</lpage></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>RJ</given-names></name></person-group><article-title>Behavioral treatment of migraine in children and adolescents</article-title><source>Paediatr Drugs</source><year>2002</year><volume>4</volume><issue>9</issue><fpage>555</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">12175270</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrasik</surname><given-names>F</given-names></name><name><surname>Grazzi</surname><given-names>L</given-names></name><name><surname>Usai</surname><given-names>S</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>D</given-names></name><name><surname>Leone</surname><given-names>M</given-names></name><name><surname>Bussone</surname><given-names>G</given-names></name></person-group><article-title>Brief neurologist-administered behavioral treatment of pediatric episodic tension-type headache</article-title><source>Neurology</source><year>2003</year><volume>60</volume><fpage>1215</fpage><lpage>1216</lpage><pub-id pub-id-type="pmid">12682344</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maratos</surname><given-names>J</given-names></name><name><surname>Wilkinson</surname><given-names>M</given-names></name></person-group><article-title>Migraine in children: a medical and psychiatric study</article-title><source>Cephalalgia</source><year>1982</year><volume>2</volume><issue>4</issue><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1982.0204179.x</pub-id><pub-id pub-id-type="pmid">7159920</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanzi</surname><given-names>G</given-names></name><name><surname>Balottin</surname><given-names>U</given-names></name><name><surname>Gamba</surname><given-names>N</given-names></name><name><surname>Fazzi</surname><given-names>E</given-names></name></person-group><article-title>Psychological aspects of migraine in children</article-title><source>Cephalalgia</source><year>1983</year><volume>3</volume><fpage>18</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1983.0302115.x</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowal</surname><given-names>A</given-names></name><name><surname>Pritchard</surname><given-names>D</given-names></name></person-group><article-title>Psychological characteristics of children who suffer from headache: a research note</article-title><source>J Child Psychol Psychiatr</source><year>1990</year><volume>31</volume><issue>4</issue><fpage>637</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1111/j.1469-7610.1990.tb00803.x</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>B</given-names></name></person-group><article-title>The role of psychological, health-behaviour and medical factors in adolescent headache</article-title><source>Dev Med Child Neurol</source><year>1988</year><volume>30</volume><issue>5</issue><fpage>616</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.1988.tb04799.x</pub-id><pub-id pub-id-type="pmid">3229559</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidetti</surname><given-names>V</given-names></name><name><surname>Galli</surname><given-names>F</given-names></name><name><surname>Fabrizi</surname><given-names>P</given-names></name><name><surname>Giannantoni</surname><given-names>AS</given-names></name><name><surname>Napoli</surname><given-names>L</given-names></name><name><surname>Bruni</surname><given-names>O</given-names></name><etal/></person-group><article-title>Headache and psychiatric comorbidity: clinical aspects and outcome in an 8-year follow-up study</article-title><source>Cephalalgia</source><year>1998</year><volume>18</volume><fpage>455</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1998.1807455.x</pub-id><pub-id pub-id-type="pmid">9793697</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fearon</surname><given-names>P</given-names></name><name><surname>Hotopf</surname><given-names>M</given-names></name></person-group><article-title>Relation between headache in childhood and physical and psychiatric symptoms in adulthood: national birth cohort study</article-title><source>BMJ</source><year>2001</year><volume>322</volume><issue>7295</issue><fpage>1145</fpage><pub-id pub-id-type="doi">10.1136/bmj.322.7295.1145</pub-id><pub-id pub-id-type="pmid">11348907</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazdin</surname><given-names>AE</given-names></name></person-group><article-title>The state of child and adolescent psychotherapy research</article-title><source>Child Adolesc Mental Health</source><year>2002</year><volume>2</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1111/1475-3588.00011</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Eccleston C, Yorke L, Morley S, Williams AC, Mastroyannopoulou K (2003) Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev (1):CD003968</mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oelkers-Ax</surname><given-names>R</given-names></name><name><surname>Leins</surname><given-names>A</given-names></name><name><surname>Parzer</surname><given-names>P</given-names></name><name><surname>Hillecke</surname><given-names>T</given-names></name><name><surname>Bolay</surname><given-names>HV</given-names></name><name><surname>Fischer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study</article-title><source>Eur J Pain</source><year>2008</year><volume>12</volume><issue>3</issue><fpage>301</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.ejpain.2007.06.003</pub-id><pub-id pub-id-type="pmid">17659990</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eccleston</surname><given-names>C</given-names></name><name><surname>Morley</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Yorke</surname><given-names>L</given-names></name><name><surname>Mastroyannopoulou</surname><given-names>K</given-names></name></person-group><article-title>Systematic review of randomized controlled trials of psychological therapy for chronic pain in children and adolescents, with a subset meta-analysis of pain relief</article-title><source>Pain</source><year>2002</year><volume>99</volume><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(02)00072-6</pub-id><pub-id pub-id-type="pmid">12237193</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Larsson B, Carlsson J, Fichtel A, Melin L (2005) Relaxation treatment of adolescent headache sufferers: results from a school-based replication series. Headache 45:692&#x02013;04</mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rains</surname><given-names>JC</given-names></name><name><surname>Penzien</surname><given-names>DB</given-names></name><name><surname>McCrory</surname><given-names>DC</given-names></name><name><surname>Gray</surname><given-names>RN</given-names></name></person-group><article-title>Behavioral headache treatment: history, review of the empirical literature, and methodological critique</article-title><source>Headache</source><year>2005</year><volume>45</volume><fpage>92</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2005.4502003.x</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarafino</surname><given-names>EP</given-names></name><name><surname>Goehring</surname><given-names>P</given-names></name></person-group><article-title>Age comparisons in acquiring biofeedback control and success in reduction headache pain</article-title><source>Ann Behav Med</source><year>2000</year><volume>22</volume><fpage>10</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/BF02895163</pub-id><pub-id pub-id-type="pmid">10892524</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grazzi</surname><given-names>L</given-names></name><name><surname>Andrasik</surname><given-names>F</given-names></name><name><surname>Usai</surname><given-names>S</given-names></name><name><surname>Bussone</surname><given-names>G</given-names></name></person-group><article-title>Magnesium as a treatment for paediatric tension-type headache: a clinical replication series</article-title><source>Neurol Sci</source><year>2005</year><volume>25</volume><fpage>338</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1007/s10072-004-0367-4</pub-id><pub-id pub-id-type="pmid">15729497</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anttila</surname><given-names>P</given-names></name></person-group><article-title>Tension-type headache in children and adolescents</article-title><source>Curr Pain Headache Rep</source><year>2004</year><volume>8</volume><issue>6</issue><fpage>500</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1007/s11916-004-0073-1</pub-id><pub-id pub-id-type="pmid">15509465</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Arafeh</surname><given-names>I</given-names></name></person-group><article-title>Chronic tension-type headache in children and adolescents</article-title><source>Cephalalgia</source><year>2001</year><volume>21</volume><fpage>830</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1046/j.0333-1024.2001.00275.x</pub-id><pub-id pub-id-type="pmid">11737009</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>SD</given-names></name></person-group><article-title>Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review)</article-title><source>Neurology</source><year>2000</year><volume>55</volume><fpage>754</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">10993991</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benedetti</surname><given-names>F</given-names></name><name><surname>Mayberg</surname><given-names>HS</given-names></name><name><surname>Wager</surname><given-names>TD</given-names></name><name><surname>Stohler</surname><given-names>CS</given-names></name><name><surname>Zubieta</surname><given-names>JK</given-names></name></person-group><article-title>Neurobiological mechanisms of the placebo effect</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><fpage>10390</fpage><lpage>10402</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3458-05.2005</pub-id><pub-id pub-id-type="pmid">16280578</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>R</given-names></name><name><surname>Collin</surname><given-names>B</given-names></name></person-group><article-title>An association between migraine and cutaneous allodynia</article-title><source>Ann Neurol</source><year>2000</year><volume>47</volume><fpage>614</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1002/1531-8249(200005)47:5&#x0003c;614::AID-ANA9&#x0003e;3.0.CO;2-N</pub-id><pub-id pub-id-type="pmid">10805332</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eidlitz-Markus</surname><given-names>T</given-names></name><name><surname>Shuper</surname><given-names>A</given-names></name><name><surname>Gorali</surname><given-names>O</given-names></name><name><surname>Zeharia</surname><given-names>A</given-names></name></person-group><article-title>Migraine and cephalic cutaneous allodynia in pediatric patients</article-title><source>Headache</source><year>2007</year><volume>47</volume><fpage>1219</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2007.00892.x</pub-id><pub-id pub-id-type="pmid">17883532</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>RM</given-names></name><name><surname>MacGregor</surname><given-names>DL</given-names></name></person-group><article-title>Management of pediatric migraine: current concepts and controversies</article-title><source>Indian J Pediatr</source><year>2008</year><volume>75</volume><issue>11</issue><fpage>1139</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1007/S12098-008-0238-8</pub-id><pub-id pub-id-type="pmid">19132316</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e4;m&#x000e4;l&#x000e4;inen</surname><given-names>ML</given-names></name><name><surname>Hoppu</surname><given-names>K</given-names></name><name><surname>Valkeila</surname><given-names>E</given-names></name><name><surname>Santavuori</surname><given-names>P</given-names></name></person-group><article-title>Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study</article-title><source>Neurology</source><year>1997</year><volume>48</volume><fpage>102</fpage><lpage>107</lpage></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>DW</given-names></name><name><surname>Kellstein</surname><given-names>D</given-names></name><name><surname>Dahl</surname><given-names>G</given-names></name><name><surname>Burke</surname><given-names>B</given-names></name><name><surname>Frank</surname><given-names>LM</given-names></name><name><surname>Toor</surname><given-names>S</given-names></name><etal/></person-group><article-title>Children&#x02019;s ibuprofen suspension for the acute treatment of pediatric migraine headache</article-title><source>Headache</source><year>2002</year><volume>42</volume><fpage>780</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2002.02180.x</pub-id><pub-id pub-id-type="pmid">12390641</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evers</surname><given-names>S</given-names></name><name><surname>Rahmann</surname><given-names>A</given-names></name><name><surname>Kraemer</surname><given-names>C</given-names></name><name><surname>Kurlemann</surname><given-names>G</given-names></name><name><surname>Debus</surname><given-names>O</given-names></name><name><surname>Husstedt</surname><given-names>IW</given-names></name><etal/></person-group><article-title>Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen</article-title><source>Neurology</source><year>2006</year><volume>67</volume><fpage>497</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000231138.18629.d5</pub-id><pub-id pub-id-type="pmid">16775229</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Hamalainen Ml, Hoppu K, Santavuori Pr (1997) Oral dihydroergotamine for therapy-resistant migraine attacks in children. Pediatr Neurol 16:114&#x02013;117</mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uebarall</surname><given-names>MA</given-names></name></person-group><article-title>Intranasal sumatriptan for the acute treatment of migraine in children</article-title><source>Neurology</source><year>1999</year><volume>52</volume><fpage>1507</fpage><lpage>1510</lpage><pub-id pub-id-type="pmid">10227648</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winner</surname><given-names>P</given-names></name><name><surname>Rothner</surname><given-names>AD</given-names></name><name><surname>Saper</surname><given-names>J</given-names></name><name><surname>Nett</surname><given-names>R</given-names></name><name><surname>Asgharnejad</surname><given-names>M</given-names></name><name><surname>Laurenza</surname><given-names>A</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents</article-title><source>Pediatrics</source><year>2000</year><volume>106</volume><fpage>989</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1542/peds.106.5.989</pub-id><pub-id pub-id-type="pmid">11061765</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahonen</surname><given-names>K</given-names></name><name><surname>H&#x000e4;m&#x000e4;l&#x000e4;inen</surname><given-names>ML</given-names></name><name><surname>Rantala</surname><given-names>H</given-names></name><name><surname>Hoppu</surname><given-names>K</given-names></name></person-group><article-title>Nasal sumatriptan is effective in the treatment of migraine attacks in children</article-title><source>Neurology</source><year>2004</year><volume>62</volume><fpage>883</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">15037686</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winner</surname><given-names>P</given-names></name><name><surname>Rothner</surname><given-names>AD</given-names></name><name><surname>Wooten</surname><given-names>JD</given-names></name><name><surname>Webster</surname><given-names>C</given-names></name><name><surname>Ames</surname><given-names>M</given-names></name></person-group><article-title>Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study</article-title><source>Headache</source><year>2006</year><volume>46</volume><fpage>212</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2006.00339.x</pub-id><pub-id pub-id-type="pmid">16492230</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamalainen</surname><given-names>M</given-names></name><name><surname>Hoppu</surname><given-names>K</given-names></name><name><surname>Santavuori</surname><given-names>P</given-names></name></person-group><article-title>Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently than adults?</article-title><source>Neurology</source><year>1997</year><volume>48</volume><fpage>1100</fpage><lpage>1103</lpage><pub-id pub-id-type="pmid">9109909</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mac Donald</surname><given-names>JT</given-names></name></person-group><article-title>Treatment of juvenile migraine with subcutaneous sumatriptan</article-title><source>Headache</source><year>1994</year><volume>34</volume><fpage>581</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1994.hed3410581.x</pub-id><pub-id pub-id-type="pmid">7843952</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linder</surname><given-names>SL</given-names></name></person-group><article-title>Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in the pediatric neurology office practice</article-title><source>Headache</source><year>1996</year><volume>36</volume><fpage>419</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.1996.3607419.x</pub-id><pub-id pub-id-type="pmid">8783473</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winner</surname><given-names>P</given-names></name><name><surname>Lewis</surname><given-names>D</given-names></name><name><surname>Visser</surname><given-names>WH</given-names></name><name><surname>Jiang</surname><given-names>K</given-names></name><name><surname>Ahrens</surname><given-names>S</given-names></name><name><surname>Evans</surname><given-names>JK</given-names></name></person-group><article-title>Rizatriptan adolescent study group. Rizatriptan 5&#x000a0;mg for the acute treatment of migraine in adolescents: a randomized, double-blind placebo-controlled study</article-title><source>Headache</source><year>2002</year><volume>42</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2002.02013.x</pub-id><pub-id pub-id-type="pmid">12005275</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>WH</given-names></name><name><surname>Winner</surname><given-names>P</given-names></name><name><surname>Strohmaier</surname><given-names>K</given-names></name><name><surname>Klipfel</surname><given-names>M</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Rizatriptan protocol 059 and 061 study groups. Rizatriptan protocol 059 and 061 study groups. Rizatriptan 5&#x000a0;mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies</article-title><source>Headache</source><year>2004</year><volume>44</volume><fpage>891</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2004.04171.x</pub-id><pub-id pub-id-type="pmid">15447698</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linder</surname><given-names>SL</given-names></name><name><surname>Dowson</surname><given-names>AJ</given-names></name></person-group><article-title>Zolmitriptan provides effective migraine relief in adolescents</article-title><source>Int J Clin Pract</source><year>2000</year><volume>54</volume><fpage>466</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">11070573</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charles</surname><given-names>JA</given-names></name></person-group><article-title>Almotriptan in the acute treatment of migraine in patients 11&#x02013;17&#x000a0;years old: an open-label pilot study of efficacy and safety</article-title><source>J Headache Pain</source><year>2006</year><volume>7</volume><fpage>95</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1007/s10194-006-0288-0</pub-id><pub-id pub-id-type="pmid">16688412</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linder</surname><given-names>SL</given-names></name><name><surname>Mathew</surname><given-names>NT</given-names></name><name><surname>Cady</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of almotriptan in adolescents: a randomized, double- blind, placebo controlled trial</article-title><source>Headache</source><year>2008</year><volume>48</volume><issue>9</issue><fpage>1326</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2008.01138.x</pub-id><pub-id pub-id-type="pmid">18484981</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>&#x02018;Ad Hoc Committee&#x02019;&#x02019;</collab></person-group><article-title>Diagnostic, therapeutic guidelines for migraine, cluster headache</article-title><source>J Headache Pain</source><year>2001</year><volume>2</volume><issue>3</issue><fpage>105</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1007/s101940100000</pub-id></mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>B</given-names></name><name><surname>McManus</surname><given-names>BC</given-names></name></person-group><article-title>Treatment of children with migraine in the emergency department: a qualitative systematic review</article-title><source>Pediatr Emerg Care</source><year>2008</year><volume>24</volume><issue>5</issue><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1097/PEC.0b013e31816ed047</pub-id><pub-id pub-id-type="pmid">18496120</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanzi</surname><given-names>G</given-names></name><name><surname>Balottin</surname><given-names>U</given-names></name><name><surname>Zambrino</surname><given-names>CA</given-names></name><name><surname>Cernibori</surname><given-names>A</given-names></name><name><surname>Del Bene</surname><given-names>E</given-names></name><name><surname>Gallai</surname><given-names>V</given-names></name><etal/></person-group><article-title>Guidelines and recommendations for the treatment of migraine in paediatric and adolescent patients</article-title><source>Funct Neurol</source><year>1996</year><volume>11</volume><fpage>269</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">9119270</pub-id></mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludvigsson</surname><given-names>J</given-names></name></person-group><article-title>Propranolol used in prophylaxis of migraine in children</article-title><source>Acta Neurol</source><year>1974</year><volume>50</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0404.1974.tb01350.x</pub-id></mixed-citation></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forsythe</surname><given-names>WI</given-names></name><name><surname>Gillies</surname><given-names>D</given-names></name><name><surname>Sills</surname><given-names>MA</given-names></name></person-group><article-title>Propranolol (Inderal) in the treatment of childhood migraine</article-title><source>Dev Med Child Neurol</source><year>1984</year><volume>26</volume><fpage>737</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.1984.tb08166.x</pub-id><pub-id pub-id-type="pmid">6519358</pub-id></mixed-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olness</surname><given-names>K</given-names></name><name><surname>Macdonald</surname><given-names>JT</given-names></name><name><surname>Uden</surname><given-names>DL</given-names></name></person-group><article-title>Comparison of self-hypnosis and propranolol in the treatment of juvenile classic migraine</article-title><source>Pediatrics</source><year>1987</year><volume>79</volume><fpage>593</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">3822681</pub-id></mixed-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sillanpaa</surname><given-names>M</given-names></name></person-group><article-title>Clonidine prophylaxis of childhood migraine and other vascular headache. A double blind study of 57 children</article-title><source>Headache</source><year>1977</year><volume>17</volume><fpage>28</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1977.hed1701028.x</pub-id><pub-id pub-id-type="pmid">321395</pub-id></mixed-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sills</surname><given-names>M</given-names></name><name><surname>Congdon</surname><given-names>P</given-names></name><name><surname>Forsythe</surname><given-names>I</given-names></name></person-group><article-title>Clonidine and childhood migraine</article-title><source>Dev Med Child Neurol</source><year>1982</year><volume>24</volume><fpage>837</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.1982.tb13704.x</pub-id><pub-id pub-id-type="pmid">6218003</pub-id></mixed-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidetti</surname><given-names>V</given-names></name><name><surname>Moscato</surname><given-names>D</given-names></name><name><surname>Ottaviano</surname><given-names>S</given-names></name><name><surname>Fiorentino</surname><given-names>D</given-names></name><name><surname>Fornara</surname><given-names>R</given-names></name></person-group><article-title>Flunarizine and migraine in childhood: an evaluation of endocrine function</article-title><source>Cephalalgia</source><year>1987</year><volume>7</volume><fpage>263</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1987.0704263.x</pub-id><pub-id pub-id-type="pmid">3427627</pub-id></mixed-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorge</surname><given-names>F</given-names></name><name><surname>Simone</surname><given-names>R</given-names></name><name><surname>Marano</surname><given-names>E</given-names></name><name><surname>Nolano</surname><given-names>M</given-names></name><name><surname>Orefice</surname><given-names>G</given-names></name><name><surname>Carrieri</surname><given-names>P</given-names></name></person-group><article-title>Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled crossover study</article-title><source>Cephalalgia</source><year>1988</year><volume>8</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1988.0801001.x</pub-id><pub-id pub-id-type="pmid">3282670</pub-id></mixed-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visudtibhan</surname><given-names>A</given-names></name><name><surname>Lusawat</surname><given-names>A</given-names></name><name><surname>Chiemchanya</surname><given-names>S</given-names></name><name><surname>Visudhiphan</surname><given-names>P</given-names></name></person-group><article-title>Flunarizine for prophylactic treatment of childhood migraine</article-title><source>J Med Assoc Thai</source><year>2004</year><volume>87</volume><issue>12</issue><fpage>1466</fpage><lpage>1470</lpage><pub-id pub-id-type="pmid">15822542</pub-id></mixed-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battistella</surname><given-names>PA</given-names></name><name><surname>Ruffilli</surname><given-names>R</given-names></name><name><surname>Moro</surname><given-names>R</given-names></name><name><surname>Fabiani</surname><given-names>M</given-names></name><name><surname>Bertoli</surname><given-names>S</given-names></name><name><surname>Antolini</surname><given-names>A</given-names></name><etal/></person-group><article-title>A placebo-controlled crossover trial of nimodipine in pediatric migraine</article-title><source>Headache</source><year>1990</year><volume>30</volume><fpage>264</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1990.hed3005264.x</pub-id><pub-id pub-id-type="pmid">2191938</pub-id></mixed-citation></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillies</surname><given-names>D</given-names></name><name><surname>Sills</surname><given-names>M</given-names></name><name><surname>Forsythe</surname><given-names>I</given-names></name></person-group><article-title>Pizotifen (Sandomigran) in childhood migraine. A double-blind placebo controlled trial</article-title><source>Eur Neurol</source><year>1986</year><volume>25</volume><fpage>32</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1159/000115983</pub-id><pub-id pub-id-type="pmid">3510125</pub-id></mixed-citation></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>DW</given-names></name><name><surname>Diamond</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>V</given-names></name></person-group><article-title>Prophylactic treatment of pediatric migraine</article-title><source>Headache</source><year>2004</year><volume>44</volume><fpage>230</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2004.04052.x</pub-id><pub-id pub-id-type="pmid">15012660</pub-id></mixed-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battistella</surname><given-names>PA</given-names></name><name><surname>Ruffilli</surname><given-names>R</given-names></name><name><surname>Cernetti</surname><given-names>R</given-names></name><name><surname>Pettenazzo</surname><given-names>A</given-names></name><name><surname>Baldin</surname><given-names>L</given-names></name><name><surname>Bertoli</surname><given-names>S</given-names></name><etal/></person-group><article-title>A placebo-controlled crossover trial using trazodone in pediatric migraine</article-title><source>Headache</source><year>1993</year><volume>33</volume><issue>1</issue><fpage>36</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1993.hed3301036.x</pub-id><pub-id pub-id-type="pmid">8436497</pub-id></mixed-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hershey</surname><given-names>AD</given-names></name><name><surname>Powers</surname><given-names>SW</given-names></name><name><surname>Bentti</surname><given-names>AL</given-names></name><name><surname>Degrauw</surname><given-names>TJ</given-names></name></person-group><article-title>Effectiveness of amitriptyline in the prophylactic management of childhood headaches</article-title><source>Headache</source><year>2000</year><volume>40</volume><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2000.00085.x</pub-id><pub-id pub-id-type="pmid">10940092</pub-id></mixed-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caruso</surname><given-names>JM</given-names></name><name><surname>Brown</surname><given-names>WD</given-names></name><name><surname>Exil</surname><given-names>G</given-names></name><name><surname>Gascon</surname><given-names>GG</given-names></name></person-group><article-title>The efficacy of divalproex sodium in the prophylactic treatment of children with migraine</article-title><source>Headache</source><year>2000</year><volume>40</volume><fpage>672</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2000.040008672.x</pub-id><pub-id pub-id-type="pmid">10971664</pub-id></mixed-citation></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serdaroglu</surname><given-names>G</given-names></name><name><surname>Erhan</surname><given-names>E</given-names></name><name><surname>Tekgul</surname><given-names>H</given-names></name><name><surname>Oksel</surname><given-names>F</given-names></name><name><surname>Erermis</surname><given-names>S</given-names></name><name><surname>Uyar</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sodium valproate prophylaxis in childhood migraine</article-title><source>Headache</source><year>2002</year><volume>42</volume><fpage>819</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2002.02186.x</pub-id><pub-id pub-id-type="pmid">12390647</pub-id></mixed-citation></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hershey</surname><given-names>AD</given-names></name><name><surname>Powers</surname><given-names>SW</given-names></name><name><surname>Vockell</surname><given-names>AL</given-names></name><name><surname>LeCates</surname><given-names>S</given-names></name><name><surname>Kabbouche</surname><given-names>M</given-names></name></person-group><article-title>Effectiveness of topiramate in the prevention of childhood headache</article-title><source>Headache</source><year>2002</year><volume>42</volume><fpage>810</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2002.02185.x</pub-id><pub-id pub-id-type="pmid">12390646</pub-id></mixed-citation></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winner</surname><given-names>P</given-names></name><name><surname>Pearlman</surname><given-names>EM</given-names></name><name><surname>Linder</surname><given-names>SL</given-names></name><name><surname>Jordan</surname><given-names>DM</given-names></name><name><surname>Fisher</surname><given-names>AC</given-names></name><name><surname>Hulihan</surname><given-names>J</given-names></name></person-group><article-title>Topiramate pediatric migraine study investigators. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial</article-title><source>Headache</source><year>2005</year><volume>45</volume><issue>10</issue><fpage>1304</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2005.00262.x</pub-id><pub-id pub-id-type="pmid">16324162</pub-id></mixed-citation></ref><ref id="CR67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>D</given-names></name><name><surname>Winner</surname><given-names>P</given-names></name><name><surname>Saper</surname><given-names>J</given-names></name><name><surname>Ness</surname><given-names>S</given-names></name><name><surname>Polverejan</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Kurland</surname><given-names>CL</given-names></name><name><surname>Nye</surname><given-names>J</given-names></name><name><surname>Yuen</surname><given-names>E</given-names></name><name><surname>Eerdekens</surname><given-names>M</given-names></name><name><surname>Ford</surname><given-names>L</given-names></name></person-group><article-title>Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17&#x000a0;years of age</article-title><source>Pediatrics</source><year>2009</year><volume>123</volume><issue>3</issue><fpage>924</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1542/peds.2008-0642</pub-id><pub-id pub-id-type="pmid">19255022</pub-id></mixed-citation></ref><ref id="CR68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>GS</given-names></name></person-group><article-title>Efficacy and safety of levetiracetam in pediatric migraine</article-title><source>Headache</source><year>2004</year><volume>44</volume><fpage>238</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2004.04053.x</pub-id><pub-id pub-id-type="pmid">15012661</pub-id></mixed-citation></ref><ref id="CR69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pakalnis</surname><given-names>A</given-names></name><name><surname>Kring</surname><given-names>D</given-names></name><name><surname>Meier</surname><given-names>L</given-names></name></person-group><article-title>Levetiracetam prophylaxis in pediatric migraine&#x02014;an open-label study</article-title><source>Headache</source><year>2007</year><volume>47</volume><issue>3</issue><fpage>427</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2007.00728.x</pub-id><pub-id pub-id-type="pmid">17371359</pub-id></mixed-citation></ref><ref id="CR70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belman</surname><given-names>Al</given-names></name><name><surname>Milazo</surname><given-names>M</given-names></name><name><surname>Savatic</surname><given-names>M</given-names></name></person-group><article-title>Gabapentin for migraine prophylaxis in children</article-title><source>Ann Neurol</source><year>2001</year><volume>50</volume><issue>Suppl.1</issue><fpage>S109</fpage></mixed-citation></ref><ref id="CR71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pakalnis</surname><given-names>A</given-names></name><name><surname>Kring</surname><given-names>D</given-names></name></person-group><article-title>Zonisamide prophylaxis in refractory pediatric headache</article-title><source>Headache</source><year>2006</year><volume>46</volume><issue>5</issue><fpage>804</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2006.00455.x</pub-id><pub-id pub-id-type="pmid">16643584</pub-id></mixed-citation></ref><ref id="CR72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>W&#x000f6;ber</surname><given-names>C</given-names></name><name><surname>Br&#x000fc;cke</surname><given-names>T</given-names></name><name><surname>W&#x000f6;ber-Bing&#x000f6;l</surname><given-names>C</given-names></name><name><surname>Asenbaum</surname><given-names>S</given-names></name><name><surname>Wessely</surname><given-names>P</given-names></name><name><surname>Podreka</surname><given-names>I</given-names></name></person-group><article-title>Dopamine D2 receptor blockade and antimigraine action of flunarizine</article-title><source>Cephalalgia</source><year>1994</year><volume>14</volume><issue>3</issue><fpage>235</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1994.014003235.x</pub-id><pub-id pub-id-type="pmid">7954746</pub-id></mixed-citation></ref><ref id="CR73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>W&#x000f6;ber</surname><given-names>C</given-names></name><name><surname>W&#x000f6;ber-Bing&#x000f6;l</surname><given-names>C</given-names></name><name><surname>Koch</surname><given-names>G</given-names></name><name><surname>Wessely</surname><given-names>P</given-names></name></person-group><article-title>Long-term results of migraine prophylaxis with flunarizine and beta-blockers</article-title><source>Cephalalgia</source><year>1991</year><volume>11</volume><issue>6</issue><fpage>251</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1991.1106251.x</pub-id><pub-id pub-id-type="pmid">1790569</pub-id></mixed-citation></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anttila</surname><given-names>P</given-names></name><name><surname>Mets&#x000e4;honkala</surname><given-names>L</given-names></name><name><surname>Aromaa</surname><given-names>M</given-names></name><name><surname>Sourander</surname><given-names>A</given-names></name><name><surname>Salminen</surname><given-names>J</given-names></name><name><surname>Helenius</surname><given-names>H</given-names></name><etal/></person-group><article-title>Determinants of tension-type headache in children</article-title><source>Cephalalgia</source><year>2002</year><volume>22</volume><fpage>401</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2002.00381.x</pub-id><pub-id pub-id-type="pmid">12110116</pub-id></mixed-citation></ref><ref id="CR75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anttila</surname><given-names>P</given-names></name></person-group><article-title>Tension-type headache in childhood and adolescence</article-title><source>Lancet Neurol</source><year>2006</year><volume>5</volume><issue>3</issue><fpage>268</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(06)70376-3</pub-id><pub-id pub-id-type="pmid">16488382</pub-id></mixed-citation></ref><ref id="CR76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>TJ</given-names></name><name><surname>Lange</surname><given-names>R</given-names></name><name><surname>Voelker</surname><given-names>M</given-names></name></person-group><article-title>Aspirin in episodic tension-type headache: placebo-controlled dose-ranging comparison with paracetamol</article-title><source>Cephalalgia</source><year>2003</year><volume>23</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2003.00470.x</pub-id><pub-id pub-id-type="pmid">12534583</pub-id></mixed-citation></ref><ref id="CR77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dooley</surname><given-names>J</given-names></name></person-group><article-title>The evaluation and management of paediatric headaches</article-title><source>Paediatr Child Health</source><year>2009</year><volume>14</volume><issue>1</issue><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">19436460</pub-id></mixed-citation></ref><ref id="CR78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pini</surname><given-names>LA</given-names></name><name><surname>Del Bene</surname><given-names>E</given-names></name><name><surname>Zanchin</surname><given-names>G</given-names></name><name><surname>Sarchielli</surname><given-names>P</given-names></name><name><surname>Di Trapani</surname><given-names>G</given-names></name><name><surname>Prudenzano</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomised, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium</article-title><source>J Headache Pain</source><year>2008</year><volume>9</volume><issue>6</issue><fpage>367</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1007/s10194-008-0071-5</pub-id><pub-id pub-id-type="pmid">18815727</pub-id></mixed-citation></ref><ref id="CR79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Bene</surname><given-names>E</given-names></name><name><surname>Poggioni</surname><given-names>M</given-names></name></person-group><article-title>Typical and atypical cluster headache in childhood</article-title><source>Cephalalgia</source><year>1987</year><volume>7</volume><issue>Suppl.6</issue><fpage>S128</fpage><lpage>S130</lpage></mixed-citation></ref><ref id="CR80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evers</surname><given-names>S</given-names></name><name><surname>Frese</surname><given-names>A</given-names></name><name><surname>Majewski</surname><given-names>A</given-names></name><name><surname>Albrecht</surname><given-names>O</given-names></name><name><surname>Husstedt</surname><given-names>IW</given-names></name></person-group><article-title>Age of onset in cluster headache: the clinical spectrum (three case reports)</article-title><source>Cephalalgia</source><year>2002</year><volume>22</volume><fpage>160</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2002.00320.x</pub-id><pub-id pub-id-type="pmid">11972589</pub-id></mixed-citation></ref><ref id="CR81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNabb</surname><given-names>S</given-names></name><name><surname>Whitehouse</surname><given-names>W</given-names></name></person-group><article-title>Cluster headache-like disorder in childhood</article-title><source>Arch Dis Child</source><year>1999</year><volume>81</volume><fpage>511</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1136/adc.81.6.511</pub-id><pub-id pub-id-type="pmid">10569970</pub-id></mixed-citation></ref><ref id="CR82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spierings</surname><given-names>EL</given-names></name><name><surname>Vincent</surname><given-names>AJ</given-names></name></person-group><article-title>Familial cluster headache: occurrence in three generations</article-title><source>Neurology</source><year>1992</year><volume>42</volume><fpage>1399</fpage><lpage>1400</lpage><pub-id pub-id-type="pmid">1620353</pub-id></mixed-citation></ref><ref id="CR83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bordini</surname><given-names>CA</given-names></name><name><surname>Arruda</surname><given-names>MA</given-names></name><name><surname>Ciciarelli</surname><given-names>M</given-names></name><name><surname>Daripa</surname><given-names>M</given-names></name><name><surname>Martins Coelho</surname><given-names>J</given-names></name><name><surname>Speciali</surname><given-names>JG</given-names></name></person-group><article-title>Cluster headache: report of seven cases in three families</article-title><source>Funct Neurol</source><year>1997</year><volume>12</volume><fpage>277</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">9439945</pub-id></mixed-citation></ref><ref id="CR84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Cruz</surname><given-names>OF</given-names></name></person-group><article-title>Cluster headaches in childhood</article-title><source>Clin Pediatr</source><year>1994</year><volume>33</volume><fpage>241</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1177/000992289403300410</pub-id></mixed-citation></ref><ref id="CR85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curless</surname><given-names>RG</given-names></name></person-group><article-title>Cluster headaches in childhood</article-title><source>J Pediatr</source><year>1982</year><volume>101</volume><fpage>393</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(82)80065-6</pub-id><pub-id pub-id-type="pmid">7108660</pub-id></mixed-citation></ref><ref id="CR86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lampl</surname><given-names>C</given-names></name></person-group><article-title>Childhood-onset cluster headache</article-title><source>Pediatr Neurol</source><year>2002</year><volume>27</volume><fpage>138</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/S0887-8994(02)00406-X</pub-id><pub-id pub-id-type="pmid">12213616</pub-id></mixed-citation></ref><ref id="CR87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallai</surname><given-names>B</given-names></name><name><surname>Mazzotta</surname><given-names>G</given-names></name><name><surname>Floridi</surname><given-names>F</given-names></name><name><surname>Mattioni</surname><given-names>A</given-names></name><name><surname>Baldi</surname><given-names>A</given-names></name><name><surname>Alberti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cluster headache in childhood and adolescence: one-year prevalence in an out-patient population</article-title><source>J Headache Pain</source><year>2003</year><volume>4</volume><fpage>132</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1007/s10194-003-0047-4</pub-id></mixed-citation></ref><ref id="CR88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neubauer</surname><given-names>D</given-names></name><name><surname>Kuhar</surname><given-names>M</given-names></name><name><surname>Ravnik</surname><given-names>IM</given-names></name></person-group><article-title>Antihistamine responsive cluster headache in a teenage girl</article-title><source>Headache</source><year>1997</year><volume>37</volume><fpage>296</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.1997.3705296.x</pub-id><pub-id pub-id-type="pmid">9195770</pub-id></mixed-citation></ref><ref id="CR89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrido</surname><given-names>C</given-names></name><name><surname>Tuna</surname><given-names>A</given-names></name><name><surname>Ramos</surname><given-names>S</given-names></name><name><surname>Temudo</surname><given-names>T</given-names></name></person-group><article-title>Cluster headache in a 3&#x000a0;year old child</article-title><source>Rev Neurol</source><year>2001</year><volume>33</volume><fpage>732</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">11784969</pub-id></mixed-citation></ref><ref id="CR90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudrow</surname><given-names>L</given-names></name></person-group><article-title>Response of cluster headache attacks to oxygen inhalation</article-title><source>Headache</source><year>1981</year><volume>21</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1981.hed2101001.x</pub-id><pub-id pub-id-type="pmid">7007285</pub-id></mixed-citation></ref><ref id="CR91"><label>91.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dodick</surname><given-names>D</given-names></name><name><surname>Campbell</surname><given-names>JK</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Silberstein</surname><given-names>SD</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Dalessio</surname><given-names>DJ</given-names></name></person-group><article-title>Cluster headache. Diagnosis management and treatment</article-title><source>Wolff&#x02019;s headache and other head pain</source><year>2000</year><edition>7</edition><publisher-loc>New York</publisher-loc><publisher-name>Oxford University Press</publisher-name><fpage>283</fpage><lpage>309</lpage></mixed-citation></ref><ref id="CR92"><label>92.</label><mixed-citation publication-type="other">Majumdar A, Ahmed MA, Benton S (2008) Cluster headache in children-Experience from a specialist headache clinic. Eur J Paediatr Neurol 22</mixed-citation></ref><ref id="CR93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akyol</surname><given-names>A</given-names></name><name><surname>Kiylioglu</surname><given-names>N</given-names></name><name><surname>Aydin</surname><given-names>I</given-names></name><name><surname>Erturk</surname><given-names>A</given-names></name><name><surname>Kaya</surname><given-names>E</given-names></name><name><surname>Telli</surname><given-names>E</given-names></name><etal/></person-group><article-title>Epidemiology and clinical characteristics of migraine among school children in the Menderes region</article-title><source>Cephalalgia</source><year>2007</year><volume>27</volume><issue>7</issue><fpage>781</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2007.01343.x</pub-id><pub-id pub-id-type="pmid">17598759</pub-id></mixed-citation></ref><ref id="CR94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>SW</given-names></name><name><surname>Patton</surname><given-names>SR</given-names></name><name><surname>Hommel</surname><given-names>KA</given-names></name><name><surname>Hershey</surname><given-names>AD</given-names></name></person-group><article-title>Quality of life in paediatric migraine: characterization of age-related effects using PedsQL 4.0</article-title><source>Cephalalgia</source><year>2004</year><volume>24</volume><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2004.00652.x</pub-id><pub-id pub-id-type="pmid">14728707</pub-id></mixed-citation></ref><ref id="CR95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strine</surname><given-names>TW</given-names></name><name><surname>Okoro</surname><given-names>CA</given-names></name><name><surname>McGuire</surname><given-names>LC</given-names></name><name><surname>Balluz</surname><given-names>LS</given-names></name></person-group><article-title>The associations among childhood headaches, emotional and behavioral difficulties, and health care use</article-title><source>Pediatrics</source><year>2006</year><volume>117</volume><issue>5</issue><fpage>1728</fpage><lpage>1735</lpage><pub-id pub-id-type="doi">10.1542/peds.2005-1024</pub-id><pub-id pub-id-type="pmid">16651331</pub-id></mixed-citation></ref><ref id="CR96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karwautz</surname><given-names>A</given-names></name><name><surname>W&#x000f6;ber</surname><given-names>C</given-names></name><name><surname>Lang</surname><given-names>T</given-names></name><name><surname>B&#x000f6;ck</surname><given-names>A</given-names></name><name><surname>Wagner-Ennsgraber</surname><given-names>C</given-names></name><name><surname>Vesely</surname><given-names>C</given-names></name><etal/></person-group><article-title>Psychosocial factors in children and adolescents with migraine and tension-type headache: a controlled study and review of the literature</article-title><source>Cephalalgia</source><year>1999</year><volume>19</volume><fpage>32</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.1999.1901032.x</pub-id><pub-id pub-id-type="pmid">10099858</pub-id></mixed-citation></ref><ref id="CR97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>SW</given-names></name><name><surname>Patton</surname><given-names>SR</given-names></name><name><surname>Hommel</surname><given-names>KA</given-names></name><name><surname>Hershey</surname><given-names>AD</given-names></name></person-group><article-title>Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses</article-title><source>Pediatrics</source><year>2003</year><volume>112</volume><issue>1 Pt 1</issue><fpage>e1</fpage><lpage>e5</lpage><pub-id pub-id-type="doi">10.1542/peds.112.1.e1</pub-id><pub-id pub-id-type="pmid">12837897</pub-id></mixed-citation></ref><ref id="CR98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newacheck</surname><given-names>PW</given-names></name><name><surname>Taylor</surname><given-names>WR</given-names></name></person-group><article-title>Childhood chronic illness: prevalence, severity, and impact</article-title><source>Am J Public Health</source><year>1992</year><volume>82</volume><fpage>364</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.2105/AJPH.82.3.364</pub-id><pub-id pub-id-type="pmid">1536351</pub-id></mixed-citation></ref><ref id="CR99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hershey</surname><given-names>AD</given-names></name><name><surname>Powers</surname><given-names>SW</given-names></name><name><surname>Vockell</surname><given-names>AL</given-names></name><name><surname>LeCates</surname><given-names>S</given-names></name><name><surname>Kabbouche</surname><given-names>MA</given-names></name><name><surname>Maynard</surname><given-names>MK</given-names></name></person-group><article-title>PedMIDAS: development of a questionnaire to assess disability of migraines in children</article-title><source>Neurology</source><year>2001</year><volume>57</volume><issue>11</issue><fpage>2034</fpage><lpage>2039</lpage><pub-id pub-id-type="pmid">11739822</pub-id></mixed-citation></ref></ref-list></back></article>